BioPharmSignal logoBioPharmSignal

Biotech News

Arvinas to Report Fourth Quarter and Full Year 2025 Financial Results on February 24, 2026

Arvinas, Inc. (ARVN)Arvinas, Inc.Earnings

NEW HAVEN, Conn., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that management will review fourth quarter and full year 2025 financial results and provide a

Related news

ARVNArvinas, Inc.2026-02-24 12:00 EST

Arvinas Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update

ARVNArvinas, Inc.2026-05-12 11:05 EST

Arvinas Reports First Quarter 2026 Financial Results and Provides Corporate Update

CRISCuris Inc2026-03-12 20:27 EST

Curis to Report Fourth Quarter 2025 Financial and Operating Results and Host Conference Call and Webcast on March 19, 2026

CCCCC4 Therapeutics2026-02-26 12:00 EST

C4 Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights

KYMRKymera2026-02-26 12:00 EST

Kymera Therapeutics Announces Fourth Quarter and Full Year 2025 Financial Results and Provides a Business Update

INVAInnoviva2026-02-25 21:05 EST

Innoviva Reports Fourth Quarter and Full Year 2025 Financial Results; Highlights Recent Company Progress

FULCFulcrum Therapeutics2026-02-24 12:01 EST

Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Fourth Quarter and Full Year 2025

NRIXNurix Therapeutics2026-01-28 21:01 EST

Nurix Therapeutics Reports Fourth Quarter and Fiscal Year 2025 Financial Results and Provides a Corporate Update

KYMRKymera2026-07-28 20:01 EST

Kymera Therapeutics to Report Second Quarter 2026 Financial Results on August 5, 2026

NRIXNurix Therapeutics2026-07-09 20:01 EST

Nurix Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update

View all latest news

Arvinas, Inc.

Arvinas is a biopharmaceutical company focused on advancing a pipeline of therapeutic programs. Investors usually track how clinical data, regulatory milestones, and launch execution change the story over time.

Recent company news

ARVNArvinas, Inc.2026-06-04 12:00 EST

Arvinas Joins The Michael J. Fox Foundation’s LITE and PPMI Programs to Advance New Therapies Targeting LRRK2 for Parkinson’s Disease

ARVNArvinas, Inc.2026-05-29 20:01 EST

Arvinas to Present at Jefferies Global Healthcare Conference

ARVNArvinas, Inc.2026-05-18 14:30 EST

Arvinas Employees Give Back During Company-wide Impact Day

ARVNArvinas, Inc.2026-05-12 11:05 EST

Arvinas Reports First Quarter 2026 Financial Results and Provides Corporate Update

ARVNArvinas, Inc.2026-05-12 11:00 EST

Arvinas and Pfizer Enter into a Transaction with Rigel Pharmaceuticals for the Exclusive Global Rights of VEPPANU (vepdegestrant)

Stock data

Close
10.78 USD
Market cap
695.5M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States